News

October 22, 2020October 22, 2020

ADT Not Needed With Radiation in Favorable Intermediate-Risk PC

News

Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a ... Read more

October 20, 2020October 20, 2020

Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds

News

Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at ... Read more

October 15, 2020October 15, 2020

Trial to Test Focal Laser Ablation Therapy for Localized Prostate Cancer

News

An investigator-initiated trial soon will evaluate Clinical Laserthermia Systems’ Tranberg Thermal therapy, a focal ablation therapy, for the treatment of prostate cancer patients who have up to medium-grade, localized ... Read more

October 13, 2020October 13, 2020

New AI Algorithm Can Accurately Identify, Grade Prostate Cancer

News

A new artificial intelligence (AI) algorithm has been developed that can accurately detect and grade prostate cancer, using slide images from patient core needle prostate biopsies, a study reports. ... Read more

October 8, 2020October 8, 2020

Veru Completes Enrollment for Second Part of Phase 1/2 VERU-111 Trial

News

Veru has completed enrollment for the second portion of a Phase 1/2 study of VERU-111, its investigational therapy for men with metastatic castration-resistant prostate cancer (mCRPC) who failed to ... Read more

October 6, 2020October 6, 2020

Lantheus Seeks FDA Approval of PyL Prostate Cancer Imaging Agent

News

Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The ... Read more

October 1, 2020October 1, 2020

Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows

News

Relugolix, a form of hormone therapy for prostate cancer, has failed to significantly extend the time men with advanced disease live without acquiring resistance to castration medications, compared with ... Read more

September 29, 2020September 29, 2020

Most nmCRPC Patients Can Safely Take Full Dose of Nubeqa, Trial Analysis Shows

News

Nearly all men with non-metastatic castration-resistant prostate cancer (nmCRPC) received the full planned dose of Nubeqa (darolutamide) tablets while participating in the ARAMIS Phase 3 trial, and few required ... Read more

September 24, 2020September 24, 2020

Phase 1 Trial of Oral Treatment for Metastatic CRPC Doses First Patient

News

A first patient has been dosed in a Phase 1 clinical trial investigating the small molecule inhibitor EPI-7386 as a treatment for metastatic castration-resistant prostate cancer (CRPC), its developer, ESSA ... Read more

September 22, 2020September 22, 2020

Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations

News

Lynparza (olaparib) has been recommended for approval in the European Union to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA1 and BRCA2, two DNA repair genes. The marketing authorization ... Read more

Pin It on Pinterest